Why CMC Filings Slow Programmes Down
The Common Technical Document (CTD) format is used for regulatory submissions across the major pharmaceutical markets. Module 3, the Quality section, contains the chemistry, manufacturing, and controls data for both the drug substance and the drug product. It is the section that drug developers frequently underestimate in terms of the time and rigour required to prepare it well.
For IND submissions in the United States, FDA first-cycle CMC deficiency letters are common. For IMPD submissions in Europe, national competent authorities regularly request additional information before granting a clinical trial authorisation. In both cases, the delay between submission and the first patient dosed is extended, often by months, by issues that could have been addressed during the writing process with appropriate regulatory expertise.
What Module 3 Contains
| Module 3 Section | Content | Key Regulatory Expectation |
| 3.2.S — Drug Substance | Nomenclature, structure, synthesis, characterisation, standards, container closure | Complete route of synthesis with controls at each step; solid form defined and controlled |
| 3.2.S.3 — Characterisation | Structural confirmation, impurity profile | Relevant impurities identified, qualified, and controlled per ICH Q3A |
| 3.2.S.4 — Control of Drug Substance | Specification, analytical procedures, validation | Methods suitable for their purpose; specifications justified |
| 3.2.S.7 — Stability | Stability data supporting retest period or shelf life | ICH Q1 conditions; data from primary batches |
| 3.2.P — Drug Product | Description, formulation, manufacture, characterisation, standards | Manufacturing process described with controls; critical steps identified |
| 3.2.P.5 — Control of Drug Product | Release specification and methods | Dissolution method development and validation documented |
| 3.2.P.8 — Stability | Drug product stability supporting proposed shelf life | Photostability per ICH Q1B; representative commercial-scale batches for NDA/MAA |
The Five Most Common Module 3 Mistakes
1. Insufficient Specification Justification
A specification is only as strong as the justification behind it. Regulators expect specifications to be set based on a combination of process capability data, safety-relevant impurity thresholds, and clinical batch data. Specifications that appear to have been set arbitrarily, or that are simply taken from a pharmacopoeial monograph without justification specific to the molecule, are a routine source of questions.
2. Incomplete Impurity Qualification
ICH Q3A requires that impurities in the drug substance above threshold levels are identified and, where necessary, qualified by toxicological assessment. Submissions that list impurities without identifying them, or that rely on qualification from structurally unrelated compounds, frequently receive deficiency letters asking for additional justification. This is an area where early engagement with an experienced regulatory team is particularly valuable.
3. Poorly Described Manufacturing Processes
The manufacturing process narrative in Module 3 must describe the process in sufficient detail for a regulator to understand the critical steps and the controls applied at each stage. Descriptions that are too high-level leave regulators unable to assess the adequacy of process control, while descriptions that are too detailed create problems when the process changes. Calibrating the level of detail appropriately requires regulatory writing experience.
4. Stability Data That Does Not Support the Proposed Shelf Life
For a Phase I filing, the data required to support the proposed retest period or shelf life may be limited, but it must be sufficient to cover the duration of the intended clinical trial. ICH Q1A(R2) sets out the minimum stability data requirements. Submissions that propose a shelf life not supported by data from the appropriate ICH storage conditions, or that use accelerated data where real-time data is required, are a predictable source of delay.
5. Inconsistencies Between Sections
Module 3 is assembled from data generated by multiple teams over an extended period. Inconsistencies between sections, such as a batch size in the manufacturing description that does not match the batch numbers in the stability section, or an analytical method in section P.5 that differs from the method used to generate the data in P.8, are common in first drafts and are a straightforward but avoidable cause of regulatory questions.
Building Module 3 Progressively
The most efficient approach to Module 3 preparation is to write it in parallel with the development programme rather than as a post-hoc assembly exercise. A regulatory team that is integrated with the development project can write each section as the underlying data is generated, identify data gaps early enough to address them before the submission deadline, and ensure consistency across sections because the same team holds the full data picture.
Ardena’s regulatory teams work alongside its development and manufacturing teams across all sites, enabling this progressive CMC dossier building approach. The regulatory scientists who advise on specification setting and process control are the same people reviewing the analytical data and manufacturing process descriptions as they are developed.
